TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04317144

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based follow-up programme.
Description: Participants who are randomized to the intervention-group will have access to web-based follow-up for one year. The programme includes short films of equipment used in intensive care e.g. ventilator, suction-device. Continous renal replacement therapy , central vein catheter among other things. About 15 short films with icu-staff talking and show how the equipment works and alarm sounds. The intervention also includes lectures about how the ICU works and what problems a critically ill patient can suffer from post-icu. There is a built-in conversation tool in the programme that can be used both by the participant and the staff who works with the follow-up programme. Questionnaires is sent out 2,6 and 12 month post-icu. The questions include PTSD, Depression, QoL and physical activity. At the end of the study, participants are sent a questionnaire asking for their experience using the web-based follow up programme.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No follow-up
Description: Participants randomized to no follow-up receive e-questionnaires 2, 6 and 12 months post-ICU care. The questions are the same as in web-based follow-up intervention group and include PTSD, Depression, QoL and physical activity.
Study: NCT03300206

Intervention type: DEVICE
Intervention: Breast Biopsy
Description: A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.

Intervention type: DEVICE
Intervention: Breast Biopsy
Description: A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
Study: NCT01334918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: Administered by intravenous bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: Administered by intravenous bolus.
Study: NCT02628678

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: FOS
Study: NCT01334918

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium Tc99m sestamibi /technetium Tc99m tetrafosmin
Description: Administered by intravenous infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium Tc99m sestamibi /technetium Tc99m tetrafosmin
Description: Administered by intravenous infusion
Study: NCT00194896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
Study: NCT02209415

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up
Description: Outpatient clinic visits
Study: NCT01832675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocain, cutaneous spray, solution
Description: 10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine lozenge
Description: 25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
Study: NCT00809159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
Study: NCT02209415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT and EUS
Description: PET/CT and EUS
Study: NCT01827917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Injection on day 0、7、21
Study: NCT01530438

Intervention type: OTHER
Group type: OTHER
Intervention: MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research
Description: At T0 and T9 or 12 monts, are performed :~* Imaging : fMRI at rest and anatomical MRI~* Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ...

Intervention type: OTHER
Group type: OTHER
Intervention: MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research
Description: At T0 and T9 or 12 monts, are performed :~* Imaging : fMRI at rest and anatomical MRI~* Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ...

Intervention type: OTHER
Group type: OTHER
Intervention: MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research
Description: At T0 and T9 or 12 monts, are performed :~* Imaging : fMRI at rest and anatomical MRI~* Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ...
Study: NCT04450056

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01652417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone bolus IV 15 mg/kg/d for 3 days.
Description: methylprednisolone bolus IV 15 mg/kg/d for 3 days.
Study: NCT01248936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Study: NCT02534064

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CALIN+
Description: Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CALIN+
Description: Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
Study: NCT01930526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
Study: NCT04353336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or Hydroxychloroquine
Description: Chloroquine or Hydroxychloroquine
Study: NCT00870818

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples for safety
Description: serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples for safety
Description: serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples for safety
Description: serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples for safety
Description: serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
Study: NCT00809159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to AIN457
Study: NCT06451393

Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy with radical tumor resection surgery
Description: All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).
Study: NCT04180176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
Study: NCT01334918

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Contrast
Description: Administered by intravenous infusion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Contrast
Description: Administered by intravenous infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Procedure/Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Procedure/Surgery
Study: NCT00870818

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples for safety
Description: serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
Study: NCT02107170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: sevoflurane-based general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: total intravenous anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Study: NCT00870818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reported outcome questionnaires
Description: EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
Study: NCT02107170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study: NCT04042207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Glucose Predictive Suspend system
Description: consists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBLHU System
Description: DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBLHU System
Description: DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
Study: NCT00870818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reported outcome questionnaires
Description: EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reported outcome questionnaires
Description: EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Patient reported outcome questionnaires
Description: EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
Study: NCT00744224

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo with saline infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Single dose of 80 mg prednisolone with saline infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone and Exenatide
Description: Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
Study: NCT04014634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Single GON injection with methylprednisolone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single GON-injection with NaCl
Study: NCT04418999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Description: Active Comparator
Study: NCT04168801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: early oral refeeding
Description: Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: early oral refeeding
Description: Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
Study: NCT01141010

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Language
Description: Plain language without psychological intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Language
Description: Psychological linguistic intervention will be given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Language
Description: Psychological linguistic intervention will be given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Language
Description: Psychological linguistic intervention will be given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Language
Description: Psychological linguistic intervention will be given
Study: NCT04279548

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS
Study: NCT01898741

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 24 Gy in 3 fractions
Study: NCT03995992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sport
Description: 10 days of sport (diving or multisport), once training per day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sport
Description: 10 days of sport (diving or multisport), once training per day
Study: NCT01367483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV methylnaltrexone (MNTX)
Study: NCT03592069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 day concomitant regimen
Description: 10 Day Concomitant Hp therapy Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14 day hybrid regimen
Description: 14 Day Hybrid Hp therapy Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days.
Study: NCT01198028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO
Study: NCT03861364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2,4 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 1,4 mg/kg
Study: NCT00970359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process.
Study: NCT02725762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LT-300 Active (PBM)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LT-300 Inactive (Sham)
Study: NCT00705328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Health Care Model (PRMHLTH)
Description: Primary health care service delivery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreation Coordination Model (REC)
Description: Recreation coordination service delivery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Model (COMP)
Description: a comprehensive service delivery model consisting of PRMHLTH plus REC.
Study: NCT01945125

Intervention type: OTHER
Group type: OTHER
Intervention: rhTSH Group
Description: Patients receiving rhTSH for RIT stimulation
Study: NCT05079646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: class 1 and class 2 cavity preparation and restored with contemporary materials
Description: class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: class 1 and class 2 cavity preparation and restored with contemporary materials
Description: class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: class 1 and class 2 cavity preparation and restored with contemporary materials
Description: class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: class 1 and class 2 cavity preparation and restored with contemporary materials
Description: class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: class 1 and class 2 cavity preparation and restored with contemporary materials
Description: class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
Study: NCT00870818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reported outcome questionnaires
Description: EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of T-cell subsets
Description: CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of T-cell subsets
Description: CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
Study: NCT05079646

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: class 1 and class 2 cavity preparation and restored with contemporary materials
Description: class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
Study: NCT03968354

Intervention type: BIOLOGICAL
Intervention: Collection of additional blood tubes; Biobanking (plasma, liver tissue).
Description: * Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research

Intervention type: BIOLOGICAL
Intervention: Collection of additional blood tubes; Biobanking (plasma, liver tissue).
Description: * Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research

Intervention type: BIOLOGICAL
Intervention: Collection of additional blood tubes; Biobanking (plasma, liver tissue).
Description: * Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research

Intervention type: BIOLOGICAL
Intervention: Collection of additional blood tubes; Biobanking (plasma, liver tissue).
Description: * Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research

Intervention type: BIOLOGICAL
Intervention: Collection of additional blood tubes; Biobanking (plasma, liver tissue).
Description: * Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research
Study: NCT04546893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;